LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

17.4 -0.4

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

17.12

Massimo

17.55

Metriche Chiave

By Trading Economics

Entrata

6M

Vendite

162M

P/E

Media del settore

6.772

35.293

EPS

0.52

Margine di Profitto

3.676

Dipendenti

1,780

EBITDA

-5M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+43.02% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3B

Apertura precedente

17.8

Chiusura precedente

17.4

Notizie sul Sentiment di mercato

By Acuity

50%

50%

167 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 set 2025, 23:56 UTC

Azioni calde

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 set 2025, 22:01 UTC

I principali Market Mover

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 set 2025, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

UPS Terminates Plan to Buy Estafeta

18 set 2025, 20:31 UTC

Utili

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 set 2025, 20:26 UTC

Utili

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 set 2025, 23:43 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

18 set 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 set 2025, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

18 set 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 set 2025, 23:31 UTC

Discorsi di Mercato

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 set 2025, 22:03 UTC

Utili

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 set 2025, 22:01 UTC

Utili

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 set 2025, 21:56 UTC

Utili

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 set 2025, 21:54 UTC

Utili

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 set 2025, 21:48 UTC

Utili

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 set 2025, 21:47 UTC

Utili

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 set 2025, 21:17 UTC

Utili

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 set 2025, 21:07 UTC

Utili

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 set 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

18 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 set 2025, 20:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

18 set 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

18 set 2025, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 set 2025, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

United Parcel Service Terminates Plan to Buy Estafeta

18 set 2025, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 set 2025, 20:18 UTC

Utili

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 set 2025, 20:18 UTC

Utili

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 set 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 set 2025, 20:07 UTC

Utili

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 set 2025, 20:03 UTC

Utili

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

43.02% in crescita

Previsioni per 12 mesi

Media 25 USD  43.02%

Alto 25 USD

Basso 25 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

14.24 / 14.78Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

167 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat